MDR Conformity Assessment Routes: Which Path Is Right for Your Device?

The conformity assessment route determines how your device gets evaluated, who evaluates it, and what evidence you need to produce. Pick the wrong route and you waste months heading down a path that does not lead to your CE mark. Pick the right one and you have a clear, efficient line from where you are to where you need to be.

MDR Article 52 is the decision tree. It maps your device class to the conformity assessment procedures described in Annexes IX, X, and XI. This post breaks down each route, explains the practical differences, and helps you identify which path fits your startup's situation.

The Three Annexes: A Quick Map

Before the details, here is the landscape:

Annex IX. Quality management system assessment and assessment of technical documentation The Notified Body assesses both your QMS and your technical documentation. This is the most common route for Class IIa, IIb, and III devices. It is comprehensive. The Notified Body looks at your whole system and your specific product documentation.

Annex X. Type examination The Notified Body examines a representative sample (the "type") of your device to verify that it meets the applicable requirements. This is a product-focused assessment rather than a system-focused one.

Annex XI. Product conformity verification The Notified Body verifies that each manufactured product (or batches of products) conforms to the approved type or the technical documentation. This is about production consistency.

These annexes are not standalone choices. They combine in specific ways depending on your device class. Article 52 prescribes the allowable combinations.

Class I Devices. Self-Declaration

Route: Annex IV (EU Declaration of Conformity) based on Annex II and III documentation

For most Class I devices, no Notified Body is involved. You prepare your technical documentation per Annex II, set up your QMS per Article 10(9), draw up your EU Declaration of Conformity per Annex IV, and affix the CE mark.

The exceptions that require Notified Body involvement for Class I: - Class I devices placed on the market in sterile condition (Class Is) - Class I devices with a measuring function (Class Im) - Reusable surgical instruments (Class Ir)

For these subcategories, the Notified Body involvement is limited to the specific aspects. Sterilization validation for sterile devices, metrological aspects for measuring devices. The Notified Body does not assess your entire QMS or your full technical documentation. Just the aspects relevant to the sterile/measuring/reprocessing characteristics.

Startup implication: If your device is Class I without sterile, measuring, or reprocessing characteristics, self-certification is your path. This is the fastest and cheapest route to market, but it is not without risk. You bear full responsibility for the correctness of your conformity assessment. No external body has reviewed your work before you go to market. Market surveillance authorities can (and do) audit self-certified devices, and deficiencies discovered at that stage can result in product recalls and enforcement actions.

Class IIa Devices. Two Options

For Class IIa devices, Article 52(3) provides two conformity assessment options:

Option A: Annex IX (Chapters I and III)

The Notified Body assesses your quality management system (Chapter I of Annex IX) and performs an assessment of the technical documentation for at least one representative device per generic device group.

What this means in practice: - The NB audits your QMS (on-site audit, typically 2-3 days for a startup) - The NB reviews the technical documentation for at least one representative device - If you have multiple devices in the same generic device group, the NB samples. They do not necessarily review every single technical file individually

This is the most common route for Class IIa startups because it covers both the system (QMS) and the product (technical documentation) in a single integrated assessment.

Option B: Annex XI (Part A) + Annex VII

Product conformity verification (Annex XI Part A) combined with the manufacturer's declaration of conformity based on a full quality assurance system (Annex VII).

What this means in practice: - The NB verifies product conformity through product testing or batch audits - You declare conformity based on your QMS

This route is less common for startups. It is more typical for companies that manufacture large batches and want batch-release verification.

Which Option for a Class IIa Startup?

Annex IX is almost always the right choice. It aligns with how startups naturally operate. You build a quality system and develop a product within it. The NB assesses both. One engagement, one relationship, integrated oversight.

Tibor's recommendation is consistent: "For a startup with one or two products, Annex IX is the obvious path. You need a QMS anyway. You need technical documentation anyway. Annex IX has the NB assess both together. It is clean and efficient."

Class IIb Devices. More Scrutiny, Same Framework

For Class IIb devices, the conformity assessment is more rigorous but follows a similar structure:

Option A: Annex IX (Chapters I and III)

Same as Class IIa, but with fuller scrutiny. The NB assesses the technical documentation for each device rather than sampling by generic device group. For Class IIb, the NB conducts a more thorough review of the clinical evidence and benefit-risk analysis.

Option B: Annex X + Annex XI (Part A)

Type examination (Annex X) combined with product conformity verification (Annex XI Part A). The NB examines a representative device of the "type," and then verifies that manufactured products conform to the approved type.

What this means in practice: - Annex X: The NB receives and examines a representative sample of your device. They verify it against the technical documentation and the applicable requirements. If it passes, they issue an EU type-examination certificate. - Annex XI Part A: For ongoing production, the NB verifies that manufactured products conform to the approved type, either by examination of every product or by audit of production batches.

Which Option for a Class IIb Startup?

Annex IX remains the most practical choice for most startups. The integrated QMS + technical documentation assessment is efficient and matches the startup operating model.

Annex X + XI makes more sense for companies with high-volume manufacturing where batch-level verification is meaningful. For a startup producing small quantities or deploying software, the type examination route adds process complexity without clear benefit.

However, there is one scenario where Annex X becomes relevant: if your startup plans to have its device manufactured by multiple contract manufacturers or in multiple locations, the type examination route can provide a certified "type" that all production sites then conform to. This is a niche scenario for most startups but worth mentioning.

Class III Devices. Maximum Rigor

Class III is the highest risk class, and the conformity assessment reflects that:

The Primary Route: Annex IX (Chapters I and II)

For Class III devices, Annex IX is applied in its fullest form: - Chapter I: Full QMS assessment - Chapter II: Assessment of the technical documentation for each device

There is no sampling at Class III. The Notified Body reviews the technical documentation for every device individually. The clinical evidence assessment is detailed and rigorous.

Additional Requirements for Class III

Expert panel consultation: For Class III implantable devices and Class IIb active devices intended to administer or remove a medicinal product, the Notified Body must request a scientific opinion from the relevant expert panel on the manufacturer's clinical evaluation assessment. This is mandated by Article 54.

The expert panel consultation adds time (typically 2-4 months) and introduces another layer of scrutiny on your clinical evidence. The expert panel may raise questions or request additional evidence, which the Notified Body will relay to you.

Clinical investigation: For Class III devices, MDR Article 61(4) has a strong presumption that clinical investigation data from the device itself is necessary, unless reliance on existing clinical data from an equivalent device is adequately justified.

Alternative Route: Annex X + Annex XI (Part A)

Type examination combined with product conformity verification. Available for Class III but less common because Annex IX is usually more efficient.

The Conformity Assessment Decision Matrix

Here is a practical decision matrix for startups:

What the Notified Body Actually Does Under Each Annex

Understanding what the Notified Body physically does helps you prepare.

Under Annex IX (the most common route):

QMS Assessment (Chapter I): 1. Reviews your QMS documentation (quality manual, SOPs, processes) 2. Conducts an on-site audit of your QMS implementation 3. Interviews your team about how processes work in practice 4. Reviews records (design files, risk management files, CAPAs, complaints) 5. Issues audit findings (major non-conformities, minor non-conformities, observations) 6. Requires you to address all non-conformities before proceeding

Technical Documentation Assessment (Chapter II/III): 1. Reviews your technical file against Annex II requirements 2. Examines your GSPR checklist and the evidence for each applicable requirement 3. Reviews your clinical evaluation and clinical evidence 4. Assesses your risk management file 5. Reviews verification and validation test reports 6. Checks labeling and instructions for use for compliance 7. Issues review findings requiring your response

Under Annex X (Type Examination):

1. Reviews your technical documentation
2. Examines a physical sample of the device
3. May conduct or commission additional testing
4. Verifies the device conforms to the MDR requirements
5. Issues an EU type-examination certificate if satisfied

Under Annex XI (Product Conformity Verification):

1. Examines manufactured products (or statistical samples from batches) to verify conformity to the approved type or technical documentation
2. Issues a certificate of conformity for each product or batch that passes

Strategic Considerations for Startups

The Annex IX Advantage for Growing Companies

Annex IX is built around QMS assessment. Once your QMS is certified by the Notified Body, adding new devices becomes incrementally easier. The NB already knows your system, and the assessment for a new device focuses primarily on the technical documentation rather than re-auditing your entire QMS.

For a startup planning to develop multiple devices, this creates a valuable platform. The QMS investment made for your first device pays forward into every subsequent device.

Timing Your Notified Body Engagement

The conformity assessment route you choose affects when you should engage the Notified Body:

Annex IX: You need a functional QMS before the NB audits it. Engage the NB once your QMS is substantially implemented (not just documented). You do not need finished technical documentation at this point. The QMS audit and the technical documentation review can be scheduled separately.

Annex X: You need a complete device and complete technical documentation before the NB can examine the type. Engage the NB later in your development cycle, when you have a finished product.

Cost Implications

The conformity assessment route affects Notified Body fees:

• Annex IX: Higher initial cost (QMS audit + technical documentation review) but lower incremental cost for additional devices
• Annex X + XI: Potentially lower initial cost for a single device but higher per-device cost if you have multiple products

For most startups with limited product portfolios, the total cost difference between routes is small compared to the total regulatory spend. Choose based on operational fit, not fee optimization.

Common Mistakes in Conformity Assessment Route Selection

Mistake 1: Not choosing at all. Some startups begin regulatory work without explicitly deciding on their conformity assessment route. This leads to unfocused documentation, wasted preparation, and confusion when engaging the Notified Body.

Mistake 2: Choosing a route without confirming it with the Notified Body. Your chosen route must be one the Notified Body agrees to. Discuss it during the pre-submission meeting.

Mistake 3: Assuming you can switch routes mid-process. Switching from Annex IX to Annex X (or vice versa) mid-assessment means starting significant portions over. Commit early.

Mistake 4: Underestimating the QMS readiness for Annex IX. The NB does not audit a planned QMS. They audit an implemented QMS. Your SOPs must be in use, your records must exist, your team must be trained. If the NB shows up and your QMS is theory rather than practice, the audit will not go well.

The Bottom Line

For most MedTech startups, the conformity assessment decision is simpler than it appears. Annex IX. Quality management system and technical documentation assessment. Is the default choice for Class IIa, IIb, and III devices. It is integrated, efficient, and scales with your company as you grow.

The critical action items: 1. Classify your device correctly (this determines which routes are available) 2. Choose your conformity assessment route based on Article 52 3. Confirm the route with your Notified Body during pre-submission discussions 4. Prepare your QMS and technical documentation in alignment with the chosen route 5. Engage the Notified Body at the right time. Early enough to avoid queue-related delays, but not before your QMS is substantively operational

The conformity assessment route is not the most exciting regulatory decision you will make. But getting it right sets the foundation for everything that follows.